Our study provides evidence that genetic inhibition of mPTP exacerbates RyR2 dysfunction in CPVT by increasing activation of the CaMKII pathway and subsequent hyperphosphorylation of RyR2. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.